Microbix Biosystems Inc. (TSE:MBX - Get Free Report)'s share price was down 3.8% during trading on Thursday following insider selling activity. The company traded as low as C$0.49 and last traded at C$0.50. Approximately 188,134 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 294,601 shares. The stock had previously closed at C$0.52.
Specifically, Director Cameron Lionel Groome sold 200,000 shares of the business's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of C$0.43, for a total value of C$86,500.00.
Microbix Biosystems Price Performance
The company has a market capitalization of C$67.67 million, a P/E ratio of 12.38 and a beta of 0.34. The company's 50-day moving average price is C$0.37 and its two-hundred day moving average price is C$0.35. The company has a debt-to-equity ratio of 22.68, a current ratio of 6.62 and a quick ratio of 5.57.
Microbix Biosystems Company Profile
(
Get Free Report)
Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Microbix Biosystems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbix Biosystems wasn't on the list.
While Microbix Biosystems currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
